Radiopharma Clarity Pharmaceuticals Ltd. raised AU$203 million (US$132.22 million) in an institutional placement on Australia’s Securities Exchange to advance its late-stage pipeline of copper-based ...

An experimental gene therapy based on the prime editing technique could become an effective treatment for alternating hemiplegia of childhood, a severe and currently incurable rare disease. David ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body ...

With more-than-satisfying phase III data in hand, Minneapolis-based Celcuity Inc. is eyeing an NDA submission in the fourth quarter of this year for gedatolisib (geda) in breast cancer. Shares of the ...

An advisory committee for the U.S. Centers for Medicare & Medicaid Services endorsed a series of patient- and ...

Researchers from Biotiche Drug Discovery Srl and collaborators have discovered that modulating the activity of a specific ...

The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug ...

The chaperone protein Hsp90 is overexpressed in many cancers, where it helps protect and drive cell proliferation by ...

Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and ...

While U.S. government cost-cutting seems to be the Trump administration’s priority that consumes all others, some Republican ...

Researchers at the Fred Hutchinson Cancer Research Center found that autoantibodies targeting the exoproteome reshaped ...